LP Attorney Cameron Stephenson Appointed to Plaintiffs’ Executive Committee in GLP-1 Vision Loss MDL

On February 23, 2026, the United States District Court for the Eastern District of Pennsylvania appointed Cameron Stephenson, a shareholder at Levin Papantonio, to the Plaintiffs’ Executive Committee in the consolidated federal litigation involving glucagon-like peptide-1 (GLP-1) receptor agonist drugs and alleged non-arteritic anterior ischemic optic neuropathy (NAION).

In a case management order, Judge Karen Spencer Marston established a leadership structure for plaintiffs. The order names Stephenson and other experienced trial lawyers to the Plaintiffs’ Executive Committee, which coordinates litigation strategy, oversees discovery, and advances plaintiffs’ nationwide claims.

Stephenson’s appointment highlights his leadership in complex pharmaceutical and mass tort litigation. In this role, he will help guide pretrial proceedings and strategy as plaintiffs pursue claims that certain GLP-1 medications are linked to serious vision injuries, including NAION.

The federal litigation centralizes related cases nationwide to promote efficiency and consistency in pretrial proceedings. Plaintiffs’ Co-Lead Counsel must regularly report on the inventory of filed and anticipated cases in both federal and related state courts.

Stephenson has extensive experience representing individuals harmed by defective pharmaceutical products and medical devices, and has held leadership roles in other nationwide coordinated litigations.

About the GLP-1 Vision Loss Litigation
The litigation focuses on claims that manufacturers of GLP-1 receptor agonist medications did not adequately warn patients and healthcare providers about the risk of non-arteritic anterior ischemic optic neuropathy, a condition that can cause sudden and permanent vision loss.